All results - Prescribing and Technical Information - European Medicines Agency - EMA - US Food and Drug Administration - FDA | Evidence search

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

Remove: US Food and Drug Administration - FDA source - 10 March 2019

FDA approved Descovy in at-risk adults and adolescents for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex.

Remove: Prescribing and Technical Information filter

FSRH New Product Review: Intrauterine Ball (IUB™) SCu300B MIDI (February 2019)

Remove: Faculty of Sexual and Reproductive Healthcare source - 11 February 2019

Faculty of Sexual and Reproductive Healthcare New Product Review: Intrauterine Ball (IUBTM) SCu300B MIDI 8 February 2019 1. Description Manufactured...

Remove: Prescribing and Technical Information filter

FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)

Remove: US Food and Drug Administration - FDA source

FDA Drug Safety Communication

Remove: Prescribing and Technical Information filter

FSRH New Product Review: Kyleena® 19.5 mg Intrauterine Delivery System (January 2018, amended March 2019)

Remove: Faculty of Sexual and Reproductive Healthcare source - 04 March 2019

Faculty of Sexual and Reproductive Healthcare New Product Review: Kyleena 19.5 mg intrauterine delivery system 29 January 2018 (Amended 22 March 2019)

Remove: Prescribing and Technical Information filter

FSRH New Product Review: Levosert® Levonorgestrel Intrauterine Delivery System LNG IUS (April 2015, amended March 2019)

Remove: Faculty of Sexual and Reproductive Healthcare source - 04 March 2019

Faculty of Sexual and Reproductive Healthcare New Product Review: Levosertr intrauterine delivery system April 2015 (Amended 4 March 2019) Levosertr...

Remove: Prescribing and Technical Information filter

FDA review finds no increased risk of prostate cancer with Parkinson's disease medicines containing entacapone (Comtan, Stalevo)

Remove: US Food and Drug Administration - FDA source

FDA Drug Safety Communication

Remove: Prescribing and Technical Information filter

FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease

Remove: US Food and Drug Administration - FDA source - 02 May 2018

The Food and Drug Administration (FDA) is warning that the liver disease medicine Ocaliva (obeticholic acid) is being incorrectly dosed in some patients with moderate to severe decreases in liver...

Remove: Prescribing and Technical Information filter

FDA Drug Safety Communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric)

Remove: US Food and Drug Administration - FDA source

FDA to evaluate increased risk of heart-related death with gout medicine febuxostat (Uloric) over allopurinol based on preliminary trial data.

Remove: Prescribing and Technical Information filter

FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings

Remove: US Food and Drug Administration - FDA source

FDA requires new warning and Med Guide about GBCAs for MRI remaining in the body. No harm found with contrast retention but safety research will continue.

Remove: Prescribing and Technical Information filter

FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)

Remove: US Food and Drug Administration - FDA source

No significant increased risk from using LABA with inhaled corticosteroid drugs. Boxed Warning removed for these combination products.

Remove: Prescribing and Technical Information filter

Filter results by

Results for all evidence | Prescribing and Technical Information | European Medicines Agency - EMA 1 - 10 of 2768 sorted by relevance / date

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

FSRH New Product Review: Intrauterine Ball (IUB™) SCu300B MIDI (February 2019)

FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)

FSRH New Product Review: Kyleena® 19.5 mg Intrauterine Delivery System (January 2018, amended March 2019)

FSRH New Product Review: Levosert® Levonorgestrel Intrauterine Delivery System LNG IUS (April 2015, amended March 2019)

FDA review finds no increased risk of prostate cancer with Parkinson's disease medicines containing entacapone (Comtan, Stalevo)

FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease

FDA Drug Safety Communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric)

FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings

FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)